Translating FRESCO Clinical Trial Evidence Into Practice: Fruquintinib as Post–Standard Third-Line Therapy Followed by Trifluridine/Tipiracil in a Patient With mCRC Without Targetable Mutations

In the Clinic JR is a 54-year-old male who was diagnosed with left-side transverse colon adenocarcinoma metastatic to the peritoneum and liver (Table 1). A next-generation […]